Wright Responds To Comparative Effectiveness Push: A Talk With Ted Davis
This article was originally published in The Gray Sheet
Executive SummaryWith $1.1 billion in federal funds already committed to comparative effectiveness research and congressional lawmakers seeking to beef up the federal CER infrastructure even further, device companies ignore this hottest of trends at their peril
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.